Embracing AI is essential for companies in the life sciences sector, with 66% of surveyed respondents believing its impact will be transformational within the next 24 months. This sentiment is particularly strong in human pharma (78%) and medical devices (70%), where AI supports drug discovery and diagnostic analysis. Although adoption rates are slower among healthcare providers (52%) and animal health companies (48%) due to budget constraints and fragmented data, the consensus is clear: companies that neglect AI will lag behind.
Success in AI implementation requires defining clear, measurable objectives, as seen with AstraZeneca’s advanced tools improving clinical trial processes. A significant 97% of respondents agree that effective AI adoption is key to attracting investment. Furthermore, 98% anticipate AI will enhance patient outcomes, particularly in EMEA, where regulatory momentum is strong. This growing confidence underscores AI’s potential to revolutionize patient care by improving diagnoses and healthcare equity in the evolving life sciences landscape.
Source link
